KRS Capital Management’s Royalty Pharma RPRX Stock Holding History

KRS Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$3K	–	304
2021 Q4	$3K	Buy	+100	New	+$3.88K	﹤0.01%	376

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KRS Capital Management's RPRX Position: Q1 2022 in Review

KRS Capital Management sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 100 shares — an estimated $3K sold.

KRS Capital Management first reported a position in RPRX in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

KRS Capital Management reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
KRS Capital Management sold 100 Royalty Pharma shares in Q1 2022, an estimated $3K.
KRS Capital Management first reported a position in Royalty Pharma in Q4 2021 and held it in 1 quarter.
KRS Capital Management's Royalty Pharma position peaked at $3K in Q4 2021.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.